全球临床肿瘤学下一代测序市场 – 行业趋势和 2029 年预测

市场分析和规模

根据美国癌症协会的数据，2019 年美国新增癌症病例 170 万例，癌症死亡人数 60 万例。肺癌、前列腺癌、膀胱癌和女性乳腺癌是全球最常见的四种癌症，占所有新癌症病例的 43%。因此，随着全球癌症发病率上升，对临床肿瘤学新一代测序的需求预计将上升。临床肿瘤学新一代测序公司正在加大对工作流程自动化的投资，以提高准确性并降低样本间差异。

Data Bridge Market Research 分析，临床肿瘤学下一代测序市场在 2021 年为 5.9256 亿美元，到 2029 年将飙升至 18.253 亿美元，预计在 2022 年至 2029 年的预测期内复合年增长率为 15.1%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Next-generation sequencing is a DNA or RNA technique that permits several reactions to be carried out simultaneously. This is one of the most important applications of next-generation sequencing in oncology. In recent years, NGS has changed cancer genetics by providing researchers greater access to genomic and transcriptome data. Next-generation tumour and germline DNA sequencing is used in oncology screening for therapeutic application.

Clinical Oncology Next Generation Sequencing Market Dynamics

Drivers

• Increase in cancer cases

The clinical oncology next-generation sequencing market is projected to be significantly impacted by personalized medicine and oncology improvements. Rising cancer prevalence, high acceptance of sequencing-based diagnostics platforms among practicing oncologists, decrease in the cost of genetic sequencing, and increased government R&D funding are some of the reasons expected to boost market growth. On the other hand, high adoption of this technique over single-gene testing and higher adoption of clinical oncology next-generation sequencing technology and platforms in academia projects will fuel a slew of new opportunities, propelling the clinical oncology next generation sequencing market forward from 2022 to 2029.

• New technological Innovatives

According to the World Health Organization's (WHO) International Agency for Research on Cancer (IARC), cancer was the top cause of death worldwide in 2020, with over 10 million fatalities. In addition, 19.3 million additional cases were reported globally. New creative technologies, such as next generation sequencing, are being used to address this worldwide burden and lower mortality rates. As a result, the clinical oncology next generation market is growing at a faster rate.

• Reduction in the cost of NGS platforms

The factor aiding the market's growth is the reduction in the cost of NGS platforms. Clinical oncology next-generation sequencing approaches provide a high percentage of reads as well as low cost per read. Leading players are introducing low-cost sequencing approaches. Similarly, the worldwide clinical oncology next generation sequencing market will expand over the forecast period as more people use next generation sequencing for liquid biopsy.

Opportunities

Rapidly increasing cancer cases have become a major issue all over the world. The sickness not only kills people but also has a negative influence on countries' economies. As a result, the government and a variety of other healthcare organisations are taking steps to combat cancer's global burden. Research institutes are receiving large sums of money in order to find viable treatments and drugs. New studies are being launched to comprehensively examine the human genome.

 Restraints/Challenges

High cost coupled with technology is a major restraint to the growth of the clinical oncology next generation sequencing market in the above mentioned forecast period.  High costs connected with the installation of sequencing platforms, poor outsourced service efficiency, and limited availability of sequencing platforms in specific regional markets are all expected to restraint the overall development of the clinical oncology next-generation sequencing market.

This clinical oncology next generation sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the clinical oncology next generation sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Clinical Oncology Next Generation Sequencing Market

The COVID-19 epidemic hugely influenced the world as a whole, causing economic collapse and death. It has resulted in a worldwide pandemic that is extremely transmissible. With the advancement of technology, next-generation sequencing is becoming increasingly important in a variety of fields. From manufacturing PPE kits to inventing test kits to detect the virus and vaccines to prevent transmission, a number of pharmaceutical businesses and agencies have contributed to reducing the infection's impact. To combat the virus, businesses have strengthened their R&D and production workforce due to the increasing benefit of determining and finding the genetic sequence of a virus, which helps scientists to comprehend the virus's entire mutation, the overall influence on the next generation sequencing industry and market is expected to be beneficial.

Recent Development

• In January 2022, Agendia, Inc., a global pioneer in breast cancer precision medicine, announced a multi-year collaboration with Illumina to co-develop in vitro diagnostic (IVD) assays for oncology testing.
• In October 2021, Roche introduced the AVENIO tumour tissue CGP kit to make tailored cancer research more accessible.

Global Clinical Oncology Next Generation Sequencing Market Scope

The clinical oncology next generation sequencing market is segmented on the basis of technology, workflow, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Technology

• Whole Genome Sequencing
• Whole Exome Sequencing
• Targeted Sequencing and Resequencing Centrifuges

Workflow

• Pre-Sequencing
• Sequencing
• Data Analysis

Application

• Screening
• Sporadic Cancer
• Inherited Cancer
•  
• Companion Diagnostics
• Other Diagnostics

End-user

• Hospitals
• Clinics
• Laboratories

Clinical Oncology Next Generation Sequencing Market Regional Analysis/Insights

The clinical oncology next generation sequencing market is analysed and market size insights and trends are provided by country, technology, workflow, application and end-user as referenced above.

The countries covered in the clinical oncology next generation sequencing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the clinical oncology next generation sequencing market due to the initiatives the governments have taken up for these technologies in the countries of this region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increasing automation in this region's pre-sequencing protocols.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Clinical Oncology Next Generation Sequencing Market Share Analysis

临床肿瘤学下一代测序市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对临床肿瘤学下一代测序市场的关注有关。

临床肿瘤学下一代测序市场的一些主要参与者包括：

• Illumina 公司（美国）
• 赛默飞世尔科技公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 安捷伦科技公司（美国）
• Myriad Genetics Inc.（美国）
• 华大基因（中国）
• Perkin Elmer Inc.（美国）
• Foundation Medicine Inc.（美国）
• PacBio (美国)
• 牛津纳米孔技术有限公司（英国）
• Paradigm Diagnostics Inc.（美国）
• Caris Life Sciences（日本）
• Partek, Incorporated（美国）
• Eurofins Scientific（卢森堡）
• Qiagen (德国)

SKU-55964